Scantox Neuro Revenue
Research Services • 
Raaba, Styria, Austria • 51-100 Employees
Scantox Neuro revenue & valuation
| Annual revenue | $5,561,075 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Research Services industry and current estimated revenues | $17,800,000 |
| Total funding | No funding |
Key Contacts at Scantox Neuro
Stefan Ebner-Benke
Director In Vivo
Tina Löffler
Director Cellular And Translational Science
Vera Niederkofler
Scientific Account Director
Simon Lemmerer
Business Director
Shirin Sharghi
Scientific Account Director
Roland Rabl
Deputy Head Of Study Coordination, Scientific Account Director At Scantox Neuro
Benedikt Kien
Study Director
Tobias Pendl
Study Director
Maria Posch
Study Director At Scantox Neuro Gmbh
Estibaliz Etxeberria Rekalde
Study Director
Company overview
| Headquarters | Parkring 12, Grambach, Styria 8074, AT |
| Phone number | +4342015172 |
| Website | |
| NAICS | 5417 |
| Keywords | Contract Research Organization (Cro), Cns Research, Alzheimer'S Disease, Orphan Diseases, Parkinson'S Disease, Neuropharmacology, Huntington'S Disease, Cns Drug Development, Behavioral Tests, In Vitro Research Models, Neurodegenrative Disesae, Transgenic Research Models |
| Founded | 1999 |
| Employees | 51-100 |
| Socials |
Scantox Neuro Email Formats
Scantox Neuro uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@qps.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@qps.com | 60% |
{first name}.{last name} | john.doe@qps.com | 40% |
About Scantox Neuro
Scantox Neuro, a full-service contract research organization (CRO), has been integrated into the Scantox Group in April 2024. The company performs preclinical research. Scantox Neuro is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn the company into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer's-, Parkinson's-, Huntington's disease, other neurodegenerative disorders and Orphan diseases. Check out our websites for detailed information: Scantox Group: www.scantox.com Neuropharmacolgy: www.scantoxneuro.com
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Scantox Neuro has 23 employees across 6 departments.
Departments
Number of employees
Funding Data
Scantox Neuro has never raised funding before.
France
Australia
United States
Netherlands
Spain
Singapore
Frequently asked questions
4.8
40,000 users
